First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.

In the NewsFlorence BuchananApril 29, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, ViroCell, Farzin Farzaneh, Truell Conservation Foundation, John Hadden II, gene therapy, cell therapy, CGT, UK CDMO, UR ALL news, vector design, AAV vectors, lentivirus vectors

Introducing ViroCell Biologics. The UK’s first clinical trial focused viral vector manufacturer.

ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).

In the NewsFlorence BuchananApril 28, 2021CDMO, ViroCell, viral vector, viral vectors, AAV vectors, lentivirus vectors, gene therapy, cell therapy, CGT, Farzin Farzaneh, John W. Hadden II, Contract Pharma, UK CDMO, vector design

First UK-based clinical trial focused viral vector manufacturer announces launch

ViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.

In the news

Team ViroCell is on the road

If you’re looking for a lentiviral and retroviral vector CDMO, we’d love to connect

London New York